Li-Bin Song1,2, Song Gao1,2, Ai-Qin Zhang3, Xiang Qian3, Lu-Ming Liu4,5. 1. Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 3. Department of Integrative Oncology, Zhejiang Province Cancer Hospital, Hangzhou, 310022, China. 4. Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. liulm@163.com. 5. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. liulm@163.com.
Abstract
OBJECTIVE: To observe the clinical effects of Babaodan Capsule (, BBD) combined with Qingyi Huaji Formula (, QYHJ) in treating patients with advanced pancreatic cancer. METHODS:Eighty-one patients with advanced pancreatic cancer (from January 1, 2013 to December 31, 2014) were enrolled. Patients were assigned to two groups: QYHJ plus BBD group (40 cases) and QYHJ only group (41 cases), and there were no significant differences for other treatment between two groups. The survival and cancer-related symptoms were compared between two groups over two cycles of treatment. RESULTS: The cancer-related symptoms of patients such as ascites, jaundice, pain, abdominal distension, anorexia and Karnofsky performance status of QYHJ plus BBD group were significantly improved as compared with those of the QYHJ group (P<0.01). In addition, the 1-year survival rate of patients in QYHJ plus BBD group was longer than that in the QYHJ group (65% vs. 33%, respectively, P=0.0023). CONCLUSIONS: BBD with QYHJ is feasible treatment to prolong the survival of patients with advanced pancreatic cancer. However, it deserves to be further investigated in randomized clinical trials.
RCT Entities:
OBJECTIVE: To observe the clinical effects of Babaodan Capsule (, BBD) combined with Qingyi Huaji Formula (, QYHJ) in treating patients with advanced pancreatic cancer. METHODS: Eighty-one patients with advanced pancreatic cancer (from January 1, 2013 to December 31, 2014) were enrolled. Patients were assigned to two groups: QYHJ plus BBD group (40 cases) and QYHJ only group (41 cases), and there were no significant differences for other treatment between two groups. The survival and cancer-related symptoms were compared between two groups over two cycles of treatment. RESULTS: The cancer-related symptoms of patients such as ascites, jaundice, pain, abdominal distension, anorexia and Karnofsky performance status of QYHJ plus BBD group were significantly improved as compared with those of the QYHJ group (P<0.01). In addition, the 1-year survival rate of patients in QYHJ plus BBD group was longer than that in the QYHJ group (65% vs. 33%, respectively, P=0.0023). CONCLUSIONS:BBD with QYHJ is feasible treatment to prolong the survival of patients with advanced pancreatic cancer. However, it deserves to be further investigated in randomized clinical trials.
Entities:
Keywords:
Babaodan Capsule; Chinese medicine; Qingyi Huaji Formula; advanced pancreatic cancer
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Werner Hartwig; Charles M Vollmer; Abe Fingerhut; Charles J Yeo; John P Neoptolemos; Mustapha Adham; Ake Andrén-Sandberg; Horacio J Asbun; Claudio Bassi; Max Bockhorn; Richard Charnley; Kevin C Conlon; Christos Dervenis; Laureano Fernandez-Cruz; Helmut Friess; Dirk J Gouma; Clem W Imrie; Keith D Lillemoe; Miroslav N Milićević; Marco Montorsi; Shailesh V Shrikhande; Yogesh K Vashist; Jakob R Izbicki; Markus W Büchler Journal: Surgery Date: 2014-02-20 Impact factor: 3.982
Authors: Jianxin Liu; Yongan Chen; Zhiyun Cao; Bin Guan; Jun Peng; Youqin Chen; Zhixue Zhan; Thomas Joseph Sferra; Senthilkumar Sankararaman; Jiumao Lin Journal: J Int Med Res Date: 2020-06 Impact factor: 1.671
Authors: Jian-Hua Guan; Zhi-Yun Cao; Bin Guan; Li-Hui Wei; Jun Peng; You-Qin Chen; Thomas Joseph Sferra; Senthilkumar Sankararaman; Zhi-Xue Zhan; Jiu-Mao Lin Journal: Transl Cancer Res Date: 2021-02 Impact factor: 1.241